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Frequent supplemental immunization activities (SIAs) with the oral poliovirus vaccine
(OPV) represent the primary strategy to interrupt poliovirus transmission in the last endemic
areas.
Materials and Methods
Using a differential-equation based poliovirus transmission model tailored to high-risk areas
in Nigeria, we perform one-way and multi-way sensitivity analyses to demonstrate the im-
pact of different assumptions about routine immunization (RI) and the frequency and quality
of SIAs on population immunity to transmission and persistence or emergence of circulating
vaccine-derived polioviruses (cVDPVs) after OPV cessation.
Results
More trivalent OPV use remains critical to avoid serotype 2 cVDPVs. RI schedules with or
without inactivated polio vaccine (IPV) could significantly improve population immunity if
coverage increases well above current levels in under-vaccinated subpopulations. Similar-
ly, the impact of SIAs on overall population immunity and cVDPV risks depends on their
ability to reach under-vaccinated groups (i.e., SIA quality). Lower SIA coverage in the
under-vaccinated subpopulation results in a higher frequency of SIAs needed to maintain
high enough population immunity to avoid cVDPVs after OPV cessation.
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Conclusions
National immunization program managers in northwest Nigeria should recognize the
benefits of increasing RI and SIA quality. Sufficiently improving RI coverage and improving
SIA quality will reduce the frequency of SIAs required to stop and prevent future poliovirus
transmission. Better information about the incremental costs to identify and reach under-
vaccinated children would help determine the optimal balance between spending to in-
crease SIA and RI quality and spending to increase SIA frequency.
Introduction
Countries use a wide variety of immunization strategies for polio.[1] Routine immunization
(RI) programs vaccinate children according to an age-specific schedule throughout the year,
while supplemental immunization activities (SIAs, e.g., national immunization days and out-
break response campaigns) typically target a wide age range of children (e.g., 0–4 year olds) re-
gardless of vaccination status during a limited period of time, often linked to epidemiologic
assessment of risk for poliovirus transmission.[2, 3] The Global Polio Eradication Initiative
(GPEI) relies heavily on SIAs with oral poliovirus vaccine (OPV) to rapidly increase population
immunity, interrupt chains of transmission, and immunize children missed by RI.[4] Coun-
tries with GPEI partner support eliminated naturally occurring wild poliovirus (WPV) sero-
type 2 (WPV2) by 2000,[5] achieved apparent global interruption of WPV serotype 3 (WPV3)
transmission in 2012,[6] and limited indigenous transmission of WPV serotype 1 (WPV1) to
decreasing areas in three countries (Afghanistan, Pakistan, Nigeria).[7] However, challenges
remain to interrupt the last chains of WPV transmission in difficult-to-reach areas in these
countries despite very frequent SIAs, and many outbreaks due to exported WPVs occurred in
previously polio-free countries in the last decade.[8] Relatively lower seroconversion of OPV in
some areas [1, 9] contributes to the need for more SIAs. However, SIAs may also repeatedly
vaccinate the same accessible children while missing unvaccinated children in some communi-
ties. In addition to vaccine coverage, population immunity to transmission depends on the
mixing and numbers of under-vaccinated individuals.[10, 11]
National immunization and GPEI leaders continue to seek the most cost-effective uses of
their substantial, but finite, immunization program resources. Achieving WPV elimination in a
country requires increasing population immunity high enough to interrupt transmission.
However, once individual countries eliminate WPVs, they remain at risk of importing WPVs
from elsewhere until global eradication occurs,[12] and consequently achieving eradication re-
quires that WPV-free countries maintain high population immunity until all countries have in-
terrupted WPV transmission. Using OPV and failing to maintain high population immunity
leads to some additional potential consequences. Specifically, populations with low immunity
levels can sustain the transmission of the live, attenuated OPV virus beyond immediate con-
tacts of vaccine recipients and allow it to establish sustained transmission to ultimately result
in outbreaks of paralysis from circulating vaccine-derived poliovirus (cVDPV).[13–15] The
reality of cVDPVs as well as the very low but noticeable rate of vaccine-associated paralytic
polio (VAPP) in OPV recipients and close contacts motivate plans to discontinue all OPV use
after WPV eradication.[16, 17] The GPEI currently plans to coordinate the cessation of all se-
rotype-2-containing OPV use (OPV2 cessation) in April 2016, followed by cessation of all re-
maining OPV serotypes (OPV13 cessation) as soon as 2019 if WPV transmission stops at least
three years before that time.[4] Currently, trivalent OPV (tOPV) remains the only serotype-
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2-containing OPV in use, with serotype 2 monovalent OPV (mOPV2) representing a possible
vaccine for outbreak response in the event of a serotype 2 outbreak after OPV2 cessation. Sero-
type 1- and 3- containing OPV include mOPV1 and mOPV3, respectively, as well as tOPV and
bivalent serotype 1 and 3 OPV (bOPV).
Northwest Nigeria historically represents one of the key poliovirus reservoirs, with large
outbreaks of WPV1, cVDPV2, andWPV3 reported during the past decade and exported polio-
virus leading to outbreaks in previously polio-free countries on numerous occasions.[12, 18,
19] Increased quality and frequency of SIAs in northwest Nigeria in recent years contributed to
probable elimination of WPV3 and only 5 reported WPV1-confirmed polio cases in 2014.[7]
However, most SIAs since 2010 used bOPV. While trivalent OPV (tOPV) remains in use for
RI, coverage with 3 or more tOPV doses in northwest Nigeria remains extremely low according
to the most recent survey.[20] The limited use of tOPV for SIAs allows accumulation of suscep-
tible children in northwest Nigeria and continued poliovirus transmission and cases associated
with a cVDPV2 outbreak that started in 2005.[21, 22] Using a model for poliovirus transmis-
sion northwest Nigeria, we previously showed the importance of better reaching the under-vac-
cinated communities while maintaining high vaccination intensity in the general population to
achieve and maintain sufficient population immunity to transmission for all 3 serotypes.[10,
23] Health authorities currently plan more frequent tOPV SIAs in northwest Nigeria leading
up to coordinated OPV2 cessation (e.g., 4 tOPV SIAs during 2015), but because population im-
munity drops once homotypic OPV use stops, preventing subsequent cVDPV emergences re-
quires higher population immunity at the time of OPV cessation than the threshold needed to
stop WPV and cVDPV transmission.[24] Thus, both quality and frequency of SIAs with differ-
ent vaccines influence serotype-specific population immunity to transmission, the ability to
achieve and maintain WPV-free status, and the ability to successfully manage OPV2 cessation.
This study explores how different assumptions about the quality of RI and the quality and fre-
quency of SIAs affect population immunity and the possibility of cVDPV outbreaks after OPV
cessation. We identify the model assumptions related to immunization quality that most affect
population immunity of all three serotypes. Given the current plans for OPV2 cessation during
2016, we then focus the analysis of combinations of quality and frequency only on tOPV SIAs.
Material and Methods
We previously developed a dynamic differential-equation based model of poliovirus transmis-
sion and OPV evolution of northwest Nigeria [25] and used it to address vaccination policy
questions.[10, 23, 26] We use the same model and adopt all model inputs and assumptions
from the most recent model update that incorporates new data on RI coverage and SIA plans.
[26] We define the reference case as the model run that assumes constant model input assump-
tions and expected SIA frequency going forward. The model input values reflect the result of
an extensive expert elicitation and model calibration process across multiple settings to repro-
duce behavior consistent with the evidence, including paralytic incidence, WPV die-out,
cVDPV emergence and outbreaks (or absence thereof in some settings), vaccination coverage
surveys and data on missed children, and age distributions of cases.[15, 23, 25, 27, 28] The ref-
erence case further assumes OPV2 cessation on April 1, 2016, consistent with the current GPEI
plan,[4] although we previously reported that the expected time until cVDPV2 elimination in
northwest Nigeria and elsewhere may necessitate delaying OPV2 cessation.[26] The reference
case assumes OPV13 cessation occurs on April 1, 2019. The model divides the approximately
45 million people in the northwest zone of Nigeria comprising 7 states [25, 29] into the general
population (90%) and an under-vaccinated subpopulation (10%) characterized by relatively
lower RI and SIA coverage and preferential subpopulation mixing. The model further accounts
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for seasonality in transmission, which explain the historically highest incidence during the
summer months,[30] by varying R0 throughout the year.[23, 25]
We performed an exploratory sensitivity analysis to characterize the impacts of changing RI
and SIA model inputs on population immunity to transmission and cVDPV risks. We varied
individual inputs starting on January 1, 2015 while keeping all others at reference case values,
although in instances with potentially important interactions we varied two inputs simulta-
neously (e.g., RI coverage in both the general population and the under-vaccinated subpopula-
tion). We explored the baseline RI coverage, which represents the coverage with 3 or more
non-birth RI doses of tOPV (until OPV2 cessation in April 2016) or bOPV (after OPV2 cessa-
tion) in the general population (i.e. POL3). As we vary the baseline RI coverage, which equals
approximately 0.14 in the reference case (based on the most recent RI coverage survey in Nige-
ria [20]), we proportionately vary the birth dose coverage and the partial coverage with 1 or 2
non-birth doses, so that the baseline RI coverage linearly affects the overall effective vaccina-
tion coverage due to RI.[25] Using baseline RI coverage as a measure of overall RI immuniza-
tion performance, RI coverage in the under-vaccinated subpopulation depends directly on the
baseline RI coverage through multiplication by the relative RI coverage in the subpopulation,
which equals 0.3 in the reference case (based on prior modeling of this population [10, 23, 25,
26]). The reference case assumes no IPV use, but the exploratory analysis considers the policy
of administering an IPV dose simultaneously with the 3rd scheduled non-birth RI OPV dose.
We assume that children who receive at least one non-birth OPV dose by 3 months of age
would also receive IPV by that time as described elsewhere.[10, 31] The 3 model inputs related
to SIAs that we varied include the baseline true SIA coverage in the general population (0.85 in
the reference case), the baseline repeated missed probability in the general population (0.85 in
the reference case), and the relative SIA coverage (RSC) in the under-vaccinated subpopulation
compared to the general population (0.2 in the reference case).[23] The true SIA coverage rep-
resents the overall fraction of children under 5 years of age who receive a dose during a single
SIA, while the repeated missed probability characterizes the fraction of children targeted but
missed by the previous SIA that will not receive a dose in the current SIA.[23] Similar to RI im-
munization, the baseline values of the general population represent overall SIA performance
and proportionally affect the SIA impact in the under-vaccinated subpopulation through the
RSC.[23]
We focus on two key outcomes for each serotype: 1) population immunity to transmission
on January 1, 2016 (i.e., after applying a change in vaccination-related model inputs for one
year and shortly before planned OPV2 cessation), and 2) circulation of cVDPVs beyond one
year after serotype-specific OPV cessation, defined as prevalence of fully-reverted polioviruses
at least one year after homotypic OPV cessation above the minimum level for which the model
assumes any poliovirus can generate a non-zero force-of-infection.[25] We characterize popu-
lation immunity using the mixing-adjusted effective immune proportion (EIPM = 1-Rn/R0,
where R0 is the basic reproductive number).[10] However, EIPM varies seasonally and by sero-
type because it depends on R0, and therefore we used Rn as a universal, scaled measure of popu-
lation immunity for our analyses. We defined the mixing-adjusted net reproductive number
(Rn) as the average number of secondary infections generated by a single infection taking into
account heterogeneous mixing between age groups and subpopulations and contributions
from individuals in all immunity states.[10] Above the threshold (i.e., denoted Rn and equal to
1) each new infection will generate more new infections and an outbreak can occur, while if Rn
remains below Rn for long enough, then transmission will die out. Circulation of cVDPVs one
year or more after homotypic OPV cessation may result from failure to interrupt cVDPV
transmission before OPV cessation, or the creation of a new cVDPV emergence after OPV ces-
sation due to insufficient population immunity at the time of homotypic OPV cessation to
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prevent the occurrence of a cVDPV outbreak.[24] The reference case for the model fails to in-
terrupt the transmission of cVDPVs prior to OPV2 cessation.
The results of the exploratory sensitivity analysis led us to focus on the RSC as a primary
metric for SIA performance. We performed additional analyses with fixed true coverage and
repeated missed probability for each SIA round of 85% for the general population and we em-
phasize that maintaining this high coverage remains critical in the context of managing OPV
cessation of each serotype. We simultaneously varied RSC and the number of tOPV rounds,
while keeping the total annual number of tOPV and bOPV SIAs fixed at 9, and reported the
impacts on the Rn for serotype 2 on January 1, 2016 and whether cVDPV2s circulate for a year
or more after OPV2 cessation. For any given annual number of tOPV SIAs between 1 and 6,
we used 1% increments in RSC to determine the minimum RSC required to prevent cVDPV2s
after OPV2 cessation. We repeated the analysis for different assumptions about RI coverage
from 2015 and beyond.
Results
Fig 1 shows the population immunity in northwest Nigeria between 2014 and 2018 for the ref-
erence case, both in terms of EIPM and Rn. Serotype 3 population immunity exceeded the
threshold from the start, serotype 1 population immunity reached and sustained high enough
levels in 2014, and serotype 2 population immunity became insufficient in 2014 following a
long period of time without any tOPV SIAs, consistent with the increase in cVDPV2 cases re-
ported that year.[32] With the projected 6 total tOPV SIAs in 2014 and 2015, respectively, and
immunity associated with the cVDPV2 outbreak, population immunity reaches the threshold,
but remains close enough to sustain a low level of silent cVDPV2 circulation until after OPV2
cessation. In the absence of OPV2 vaccine after OPV2 cessation, population immunity drops
further until eventually a large cVDPV2 outbreak occurs, which would necessitate an outbreak
response with mOPV2 or tOPV from the global stockpile. With insufficient population immu-
nity to transmission at the time of OPV2 cessation, subsequent cVDPV2s could occur both due
to continued silent circulation of current cVDPVs or due to the development of new cVDPV2s
derived from tOPV used just prior to OPV2 cessation.[24] Programmatically, both of these
events would represent a public health emergency, but more tOPV use to increase population
immunity to transmission at the time of OPV2 cessation can prevent them.[24]
Table 1 shows the impact of varying model inputs related to RI starting January 1, 2015.
Changes around the currently very low RI coverage in the reference case lead to only small im-
pact on population immunity. However, given that the reference case attains serotype 2 popu-
lation immunity slightly below the level needed to avoid re-emergence of cVDPV2s after
OPV2 cessation, small increases in population immunity can prevent cVDPV2s after OPV2
cessation. For example, if the baseline RI coverage in the general population increases to 0.5,
which also increases the RI coverage in the subpopulation to 0.5×0.3 = 0.15, then cVDPV2s do
not persist after OPV2 cessation despite the tail end of the ongoing cVDPV2 outbreak lasting
up until OPV2 cessation. Seasonality plays a role in interrupting cVDPV2 transmission despite
no OPV2 vaccine, because the average number of secondary transmissions per new infection
becomes lower in the low season (i.e., as a result of the lower R0 during the low season) (Fig 1).
If both the baseline RI coverage and the relative RI coverage in the under-vaccinated subpopu-
lation increase to 0.5, then this implies a significant improvement in absolute RI coverage for
the under-vaccinated subpopulation to 0.25. This improvement results in a marked reduction
in Rn, interrupts cVDPV2 transmission by January 1, 2016, and avoids cVDPV2s after OPV2
cessation. Consistent with prior work,[10, 33] the addition of a single IPV RI dose given with
the third dose of OPV in RI from January 1, 2015 does not yield a large impact on population
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Fig 1. Population immunity in northwest Nigeria for the reference case, 2014–2017. (a) Mixing-adjusted
effective immune proportion (EIPM) compared to the threshold (EIP*). (b) Mixing-adjusted net reproductive
number (Rn) compared to threshold of Rn* = 1.
doi:10.1371/journal.pone.0130123.g001
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immunity or on cVDPV circulation after OPV cessation due to the low RI coverage in north-
west Nigeria.[25]
Table 2 shows how SIA-related model inputs influence population immunity and cVDPV
risks after OPV cessation. The baseline true SIA coverage in the general population, which di-
rectly influences the under-vaccinated subpopulation through the RSC, only moderately influ-
ences population immunity. However, a very high baseline repeated missed probability implies
more susceptible children both in the general and under-vaccinated subpopulations resulting
in markedly lower population immunity. We see that the largest impact on population immu-
nity comes from increasing coverage in the under-vaccinated subpopulation (i.e., increasing
the RSC), with Rn ranging from 0.63 for PV3 with RSC = 0.5 (i.e., very high population immu-
nity) to approximately 1 or more for all 3 serotypes with RSC = 0.1. An increase of RSC from
0.2 in the reference case to 0.25 prevents the cVDPV2s after OPV2 cessation.
None of the changes in RI and SIA model inputs we considered resulted in cVDPV1 or
cVDPV3 outbreaks after OPV13 cessation, despite similar population immunity levels to
transmission on January 1, 2016, because serotype 1 and 3 population immunity to transmis-
sion continues to increase after OPV2 cessation with all RI and SIA bOPV use, and because
our model assumes that serotype 1 and 3 OPV revert more slowly and remain relatively less
transmissible than serotype 2 OPV.[15, 23, 25, 27, 28]
Fig 2 illustrates the interactions between RSC and the annual number of tOPV rounds in
terms of population immunity and cVDPV2 risks after OPV2 cessation. The curves in Fig 2a
omit higher values of Rn for which population immunity remains insufficient to prevent persis-
tent cVDPV2s after OPV2 cessation, because these situations represent programmatic failures.
Increasing the number of tOPV SIAs clearly increases population immunity to serotype 2 (i.e.,
Table 1. Exploratory sensitivity analysis of model inputs and assumptions that characterize routine immunization (RI) (reference case shown in
italics).
Varied input(s), value(s) Rn at 1/1/2016 cVDPVs ater OPV cessation?
a
Type 1 Type 2b Type 3 Type 1 Type 2 Type 3
Baseline RI coverage (general population):
0.1 0.87 0.87* 0.83 No Yes No
0.14 (reference) 0.87 0.87* 0.83 No Yes No
0.3 0.83 0.82* 0.81 No No No
0.5 0.80 0.77* 0.78 No No No
Relative RI coverage in the under-vaccinated subpopulation:
0 0.89 0.91* 0.85 No Yes No
0.1 0.88 0.89* 0.84 No Yes No
0.3 (reference) 0.87 0.87* 0.83 No Yes No
0.5 0.85 0.84* 0.82 No No No
Baseline and relative RI coverage combined:
Baseline RI coverage = 0.139, relative RI coverage = 0.3(reference) 0.87 0.87* 0.83 No Yes No
Baseline RI coverage = 0.5, relative RI coverage = 0.5 0.75 0.70 0.75 No No No
IPV use for RI:
No IPV doses added to RI schedule (reference) 0.87 0.87* 0.83 No Yes No
1 IPV dose added to RI schedule from 1/1/2015 0.86 0.87* 0.83 No Yes No
a Defined as occurrence of fully-reverted virus prevalence above the transmission threshold (EPI*), including due to cVDPV emergence after OPV
cessation, or failure to interrupt cVDPV transmission before OPV cessation.
b Asterisk indicates continued cVDPV2 transmission at 1/1/2016, but at such low levels that it has negligible impact on Rn at January 1, 2016.
doi:10.1371/journal.pone.0130123.t001
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reduces Rn), with a larger increase between 1 and 2 SIAs than between 2 and 3 SIAs. The dis-
tance between the curves also depends on the timing of the SIAs. For example, the distance be-
tween the curves for 4 and 5 tOPV SIAs remains very small because for both scenarios the last
two SIAs conducted prior to January 1, 2016 remain the same (i.e., August and November
2015). Similarly, the curve for 6 tOPV SIAs includes a December SIA, just prior to the time
when we record Rn on January 1, 2016. For low values of RSC, population immunity can still
remain very low despite high numbers of tOPV SIAs. For the reference case assumption of
RSC = 0.2, 3 tOPV SIAs do not prevent cVDPVs after OPV2 cessation. This suggests the need
for at least 5 tOPV SIAs from early 2015 through OPV2 cessation to prevent cVDPV2s if RSC
does not improve (i.e., 4 in 2015 and 1 in March 2016). Fig 2b shows the minimum RSC needed
to prevent persistent cVDPV2s after OPV2 cessation as a function of the number of tOPV
SIAs. For example, only 1 annual tOPV SIA with an RSC of at least 0.5 from 2015 forward (in-
cluding in March 2016, shortly before OPV2 cessation) appears sufficient to prevent cVDPV2
persistence. However, with 4 tOPV SIAs, preventing cVDPV2s after OPV2 cessation requires
an RSC of only 0.15 or more. The nonlinear relationship underscores the importance of reach-
ing the under-vaccinated subpopulation, with increasingly frequent tOPV SIAs needed as RSC
decreases.
Fig 3 considers the impacts of varying levels of RI coverage, while still maintaining SIA cov-
erage at 85%. Not surprisingly, without any RI, preventing cVDPV2s after OPV2 cessation re-
quires more tOPV SIAs, higher RSC, or both compared to the reference case. If RI coverage in
the subpopulation increases to the level of the general population (i.e., relative RI coverage of
1), then this results in a notable downward curve shift, implying lower demands on RSC and/
or SIA frequency to prevent cVDPV2s after OPV2 cessation. With a moderate improvement in
Table 2. Exploratory sensitivity analysis of model inputs and assumptions that characterize SIAs (reference case shown in italics).
Varied input(s), value(s) Rn at 1/1/2016 cVDPVs afterOPV cessation?
a
Type 1 Type 2b Type 3 Type 1 Type 2 Type 3
Baseline true SIA coverage (general population):
0.75 0.90 0.89* 0.85 No Yes No
0.80 0.88 0.88* 0.84 No Yes No
0.85 (reference) 0.87 0.87* 0.83 No Yes No
0.90 0.85 0.86* 0.82 No Yes No
0.95 0.84 0.85* 0.80 No No No
Baseline repeated missed probability (general population):
0.75 0.84 0.85* 0.80 No No No
0.85 (reference) 0.87 0.87* 0.83 No Yes No
0.95 0.95 0.90* 0.90 No Yes No
Relative SIA coverage in the under-vaccinated subpopulation (RSC):
0.1 1.02 0.96* 0.97 No Yes No
0.15 0.93 0.91* 0.89 No Yes No
0.2(reference) 0.87 0.87* 0.83 No Yes No
0.25 0.81 0.83* 0.78 No No No
0.30 0.77 0.80* 0.74 No No No
0.50 0.65 0.70 0.63 No No No
a Defined as occurrence of fully-reverted virus prevalence above the transmission threshold (EPI*), including due to cVDPV emergence after OPV
cessation, or failure to interrupt cVDPV transmission before OPV cessation.
b Asterisk indicates continued cVDPV2 transmission at 1/1/2016, but at such low levels that it has negligible impact on Rn at 1/1/2016.
doi:10.1371/journal.pone.0130123.t002
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Fig 2. Interactions between tOPV SIA quality and frequency leading up to OPV2 cessation in
northwest Nigeria. Acronyms: cVDPV, circulating vaccine-derived poliovirus; OPV2, serotype 2-containing
oral poliovirus vaccine; Rn, net reproduction number; RSC, relative SIA coverage in the under-vaccinated
subpopulation; SIA, supplemental immunization activity; tOPV, trivalent oral poliovirus vaccine. (a) Impact on
Rn for type 2, omitting points for which cVDPV2s circulate beyond a year after OPV2 cessation. (b) Minimum
RSC to prevent cVDPVs after OPV2 cessation as a function the annual number of tOPV SIAs.
doi:10.1371/journal.pone.0130123.g002
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the baseline RI coverage to 0.4 and with a relative RI coverage of 0.4, 2 annual tOPV SIAs re-
main sufficient to prevent cVDPV2s after OPV2 cessation even if RSC decreases to 0.1. If RI
coverage improves to 0.5 in the general population and RSC to 0.5 (i.e., resulting in an absolute
coverage of 0.25 in the under-vaccinated subpopulation), then this significantly slows down
the accumulation of new susceptible children and loss of overall population immunity. Conse-
quently, for this level of RI coverage, a single annual SIA with high quality in the general popu-
lation can prevent cVDPV2s after OPV2 cessation, even if it does not reach the subpopulation.
However, this finding depends on high SIA coverage in the general population and on residual
immunity derived from the outbreak and response that occurred in 2014; without these condi-
tions, preventing cVDPV2s after OPV2 cessation may require higher RI coverage.
Discussion
Achieving and maintaining high population immunity for all 3 serotypes remains critical for
both sustained WPV elimination and successful management of OPV cessation.[10, 24, 31, 34]
Fig 3. Interaction between tOPV SIA quality, SIA frequency, and RI coverage in northwest Nigeria. Acronyms: cVDPV, circulating vaccine-derived
poliovirus; OPV2, serotype 2-containing oral poliovirus vaccine; RI, routine immunization; RSC, relative SIA coverage in the under-vaccinated subpopulation;
SIA, supplemental immunization activity; tOPV, trivalent oral poliovirus vaccine.
doi:10.1371/journal.pone.0130123.g003
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The safest and most efficient way to successfully eradicate WPV and transition to the post-
OPV era involves more intense vaccination than the strict minimum needed to reach the
threshold population immunity level.[24, 35] Investments made to improve RI and/or SIAs all
affect population immunity and reduce the risk of cVDPVs after OPV cessation. While small
numerical increments in RI or SIA quality can yield the same effect on population immunity
and cVDPV risks as added SIA rounds, these may represent large increases in practice, which
require active outreach activities and extensive efforts to identify under-served population pre-
viously missed by population censuses and vaccination campaigns,[36] sometimes in the con-
text of security challenges. Program managers should compare the feasibility and cost of these
different options, particularly related to reaching under-vaccinated subpopulations compared
to and in addition to conducting frequent rounds. Programs should focus on overall perfor-
mance and ensure that they achieve sustained population immunity well above the threshold
everywhere and for each serotype through cessation of homotypic OPV.[37] Although our
analysis of SIAs focused primarily on the importance of reaching the under-vaccinated sub-
populations given the range of SIA coverage considered in the exploratory sensitivity analyses,
maintaining high SIA coverage in the general population represents a critical factor that also af-
fects the results and remains essential in efforts to sustain overall population immunity and
prevent outbreaks of imported poliovirus or cVDPVs.[8]
Our finding of the limited impact of IPV on population immunity to transmission, and thus
its ability to prevent cVDPV emergence remains consistent with our earlier findings [33] and
the literature on IPV-induced immunity,[27, 28] including a recent study that showed that IPV
provides a better boost in individual intestinal immunity than bOPV.[38] Our model assumes
that both successful IPV immunization and successful OPV immunization “takes” return indi-
viduals with prior potentially waned live poliovirus-induced immunity to the highest state of
immunity in the model.[25] However, for OPV, the model uses an effectively lower “take” of
the booster dose given oral administration by accounting for the relative susceptibility of the
prior immunity state (i.e., between 0.2 for recent immunity and 0.8 for the last waning stage),
while for an IPV dose we assume no reduction in the “take” due to prior immunity.[25] In ad-
dition, we assume a higher per-dose take rate for IPV than bOPV (i.e., 0.63 vs. 0.54 in the Nige-
ria model).[23] The significant difference in the effective take of IPV compared to bOPV
explains the significant difference in the intestinal immunity observed at the individual level in
a recent clinical trial.[38]
At the population level, which represents the critical perspective for poliovirus transmission
and overall national immunization program performance,[37] our model suggests only a moder-
ate role of individuals with prior live poliovirus-induced immunity on overall population
immunity, with fully susceptible individuals driving the overall population immunity to trans-
mission, particularly since they mix preferentially within their age group and/or subpopulation.
[10, 23] Numerous prior studies demonstrated very limited intestinal immunity provided by
IPV-only in fully susceptible individuals,[27, 39, 40] which implies a very limited impact of IPV
alone on population immunity in settings conducive to fecal-oral poliovirus transmission.[33,
41–43] Moreover, OPV provides additional population immunity to transmission through sec-
ondary immunization of vaccine recipients while IPV does not. Consequently, despite the better
ability of IPV to boost individual intestinal immunity in individuals with prior live poliovirus-in-
duced immunity, our analyses suggest little overall impact of low-coverage IPV RI on population
immunity in northwest Nigeria. Further analyses of IPV coupled with higher RI coverage or used
in SIAs remains beyond the scope of this work, but we anticipate only marginal improvements
given the inherent properties of IPV. Nevertheless, after OPV cessation, IPV will represent the
only available poliovirus vaccine to provide some measure of population immunity to transmis-
sion in the long-term and to prevent paralytic cases in the event of a poliovirus reintroduction.
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Many model inputs remain uncertain. However, changing the model inputs not directly re-
lated to vaccination from 2015 forward might lead to results inconsistent with the past experi-
ence in northwest Nigeria and would require refitting the model. We focused on changes of the
vaccination inputs with all other inputs held constant, and consequently we did not consider
the uncertainty about the non-vaccination inputs in our analyses. Although the reference case
estimates of the vaccination inputs remain uncertain, including the relative RI and SIA cover-
age in the under-vaccinated subpopulation, the process of fitting the northwest Nigeria model
to the actual experience provides some confidence that the combination of model inputs gives
an adequate approximation of the situation in this conceptual subpopulation.[23, 25] We rec-
ognize that translating the conceptual under-vaccinated subpopulation into real people in the
field may prove difficult. For example, in reality the under-vaccinated subpopulation, which we
estimated as 10% of the total Nigerian northwest population, may include unevenly distributed
pockets of communities in hard-to-reach rural areas, as well as under-served urban groups,
and as the coverage in these population improves the size of the truly under-vaccinated
population decreases.
Despite the uncertainties, the model confirms the experience of other countries (most notably
India) that did not succeed in eliminatingWPV until they identified and vaccinated large clusters
of under-vaccinated people that sustainedWPV transmission.[44] Continuing to improve vacci-
nation coverage among historically under-vaccinated groups in northwest Nigeria can greatly
facilitate the transition to OPV2 cessation and decrease the overall burden of paralytic polio.
Without these improvements, a high frequency of tOPV rounds until OPV2 cessation and
bOPV rounds until OPV13 cessation remains necessary. Thus, the use of tOPV for SIAs contin-
ues to represent an important consideration. While Nigeria must maintain high population im-
munity for serotype 1 to stopWPV1 and prevent any subsequent WPV1 importations, doing so
at the expense of immunity to serotype 2 may delay or undermine successful OPV2 cessation.
While, using more tOPV at the expense of more bOPVmust not undermine serotype 1 and 3
immunity, bOPV SIAs provide no boost in population immunity to transmission at all for sero-
type 2, whereas tOPV SIAs provide a considerable boost in population immunity to transmission
for serotypes 1 and 3. Further modeling studies can help inform decisions related to choices of
the number of bOPV vs. tOPV SIAs leading up to OPV2 cessation and bOPV SIAs quality and
frequency leading up to OPV13 cessation,[45] and the optimal timing of SIAs relative to OPV
cessation and seasonality. In addition, they might expand these analyses to consider other high-
risk populations in the world (e.g., those with relatively higher R0 and lower OPV take rates).
Conclusions
To achieve and maintain sufficiently high population immunity to transmission and prevent
reintroduction of WPVs and cVDPVs in northwest Nigeria, national immunization program
managers should consider the interactions of immunization activities as they allocate resources
to strengthening RI services and increasing the frequency and quality of SIAs. Improving the
quality of RI and SIAs to reach under-vaccinated groups reduces the frequency of SIAs needed
to maintain high enough population immunity. While the model assumptions for northwest
Nigeria, including the characteristics of the under-vaccinated subpopulation may differ for
high-risk populations in different areas of the world, the qualitative insights of this work extend
to all high-risk populations.
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